Biotech · Private company
Napo Pharmaceuticals, Inc.
Track this companyFree. Adds Napo Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials62 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- Crofelemer 125 MG [Mytesi]Phase 3 · Cancer Therapy-Related DiarrheaClinicalTrials.gov · fetched Nov 12, 2026
- Crofelemer Powder for Oral SolutionPhase 3 · Microvillus Inclusion DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Crofelemer delayed-release tablets 125mgAcquired Immunodeficiency SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)PHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started May 1, 2025ClinicalTrials.gov NCT06721871 · fetched Nov 12, 2026
- Open-Label Pilot Study With Crofelemer in Patients With Short Bowel SyndromeEARLY_PHASE1 · ACTIVE_NOT_RECRUITING · started Mar 3, 2025ClinicalTrials.gov NCT06326645 · fetched Nov 12, 2026
- Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer TherapyPHASE3 · COMPLETED · started Oct 7, 2020ClinicalTrials.gov NCT04538625 · fetched Nov 12, 2026
- Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious DiarrheaPHASE4 · COMPLETED · started Oct 22, 2019ClinicalTrials.gov NCT04192487 · fetched Nov 12, 2026
- Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV PatientsPHASE4 · COMPLETED · started Apr 1, 2019ClinicalTrials.gov NCT03898856 · fetched Nov 12, 2026
- Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer PatientsPHASE2 · COMPLETED · started Jan 31, 2017ClinicalTrials.gov NCT02910219 · fetched Nov 12, 2026